Revolutionary contrast reduction,
uncompromised imaging.
At Osprey Medical, our mission is to improve outcomes in patients with Chronic Kidney Disease by reducing contrast induced Acute Kidney Injury (AKI) and lowering hospital costs. Osprey’s proprietary technologies reduce the amount of contrast (dye) injected into patients during heart catheterization procedures without compromising X-ray image quality for the physician.
Our vision is to make angiography safer for CKD patients.
Dr. Paul Tucker, Interventional Cardiologist in Austin, Texas discusses his hospital’s quality improvement program to reduce Contrast-Induced Acute Kidney Injury in the Cath lab. Dr. Tucker reviews their implementation of a Kidney Care Program with the DyeVert System, the clinical and economic outcomes, and next steps for improved patient care.
The only FDA indicated technology for reducing dye dosage to patients
https://ospreymed.com/wp-content/uploads/2020/10/Supplier-Horizon-Award.jpg
600
600
Cat Gilfillen
/wp-content/uploads/2017/04/osprey-logo-224w.png
Cat Gilfillen2020-09-29 01:08:262020-10-01 01:08:51Osprey receives Supplier Horizon Award from Premier Inc
https://ospreymed.com/wp-content/uploads/2020/09/DyeVert_Logo-4C.jpg
700
700
Cat Gilfillen
/wp-content/uploads/2017/04/osprey-logo-224w.png
Cat Gilfillen2020-07-30 20:40:492020-09-30 20:42:01GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)Photo credit (Kidney Care): Blausen.com staff (2014). “Medical gallery of Blausen Medical 2014“. WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436.